Barclays PLC Novo Cure LTD Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Novo Cure LTD stock. As of the latest transaction made, Barclays PLC holds 453,705 shares of NVCR stock, worth $11.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

453,705

Previous 453,705 -0.0%

Holding current value

$11.9 Million

Previous $7.09 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$15.61 - $23.34 $2.05 Million - $3.07 Million	131,389 Added 40.76%	453,705 $7.09 Million
Q2 2024 Aug 14, 2024	BUY	$11.83 - $24.05 $1.03 Million - $2.09 Million	86,916 Added 36.92%	322,316 $5.52 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $1.61 Million - $2.25 Million	129,866 Added 123.06%	235,400 $3.68 Million
Q4 2023 Feb 15, 2024	BUY	$11.13 - $15.78 $665,062 - $942,918	59,754 Added 130.52%	105,534 $1.58 Million
Q3 2023 Nov 07, 2023	SELL	$16.15 - $42.35 $593,867 - $1.56 Million	-36,772 Reduced 44.54%	45,780 $740,000
Q2 2023 Aug 03, 2023	SELL	$40.29 - $82.51 $401,691 - $822,624	-9,970 Reduced 10.78%	82,552 $3.43 Million
Q1 2023 May 04, 2023	BUY	$56.44 - $118.81 $826,055 - $1.74 Million	14,636 Added 18.79%	92,522 $5.56 Million
Q4 2022 Feb 13, 2023	BUY	$63.98 - $85.37 $126,360 - $168,605	1,975 Added 2.6%	77,886 $5.71 Million
Q3 2022 Nov 03, 2022	BUY	$67.99 - $89.57 $357,559 - $471,048	5,259 Added 7.44%	75,911 $5.77 Million
Q2 2022 Aug 12, 2022	BUY	$56.6 - $89.9 $744,912 - $1.18 Million	13,161 Added 22.89%	70,652 $4.91 Million
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $609,379 - $856,272	-10,131 Reduced 14.98%	57,491 $4.77 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $354,227 - $575,548	-4,718 Reduced 6.52%	67,622 $5.08 Million
Q3 2021 Nov 09, 2021	SELL	$116.17 - $194.55 $1.15 Million - $1.92 Million	-9,864 Reduced 12.0%	72,340 $8.41 Million
Q2 2021 Aug 13, 2021	BUY	$130.4 - $225.58 $2.5 Million - $4.33 Million	19,200 Added 30.47%	82,204 $18.2 Million
Q1 2021 May 13, 2021	BUY	$124.11 - $190.17 $2.81 Million - $4.31 Million	22,646 Added 56.11%	63,004 $8.33 Million
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $3.2 Million - $4.97 Million	28,552 Added 241.84%	40,358 $6.98 Million
Q3 2020 Nov 12, 2020	SELL	$58.05 - $111.31 $17.5 Million - $33.5 Million	-301,409 Reduced 96.23%	11,806 $1.31 Million
Q2 2020 Aug 12, 2020	SELL	$57.2 - $74.41 $5.96 Million - $7.75 Million	-104,129 Reduced 24.95%	313,215 $18.6 Million
Q1 2020 May 13, 2020	SELL	$57.05 - $95.75 $4.76 Million - $7.98 Million	-83,352 Reduced 16.65%	417,344 $28.1 Million
Q4 2019 Feb 10, 2020	BUY	$68.3 - $93.8 $3.66 Million - $5.02 Million	53,527 Added 11.97%	500,696 $42.2 Million
Q3 2019 Nov 14, 2019	BUY	$61.86 - $97.8 $7.43 Million - $11.8 Million	120,168 Added 36.75%	447,169 $33.4 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $695,996 - $1.04 Million	16,485 Added 5.31%	327,001 $20.7 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $9.9 Million - $17.4 Million	309,711 Added 38473.42%	310,516 $15 Million
Q4 2018 Feb 14, 2019	SELL	$28.72 - $52.63 $806,744 - $1.48 Million	-28,090 Reduced 97.21%	805 $27,000
Q3 2018 Nov 14, 2018	BUY	$32.0 - $52.4 $646,048 - $1.06 Million	20,189 Added 231.9%	28,895 $1.52 Million
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $164,893 - $265,824	-8,307 Reduced 48.83%	8,706 $272,000
Q1 2018 May 15, 2018	SELL	$19.3 - $23.65 $151,061 - $185,108	-7,827 Reduced 31.51%	17,013 $371,000
Q4 2017 Feb 14, 2018	BUY	$16.3 - $21.9 $220,245 - $295,912	13,512 Added 119.28%	24,840 $502,000
Q3 2017 Nov 14, 2017	BUY	$18.05 - $21.75 $204,470 - $246,384	11,328	11,328 $226,000

Others Institutions Holding NVCR

# of Institutions

263

Shares Held

76.9M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.76B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account